Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

United States federal and state rules and regulations during public health emergencies: navigating novel coronavirus

By Scot Hasselman, Celeste Letourneau, Joseph W. Metro, Lesley Reynolds, Nicole Aiken-Shaban, Jessica Christensen, Arielle Lusardi, Kristin Parker & Janine Tougas on February 13, 2020
Email this postTweet this postLike this postShare this post on LinkedIn

On January 30, 2020, the World Health Organization (WHO) declared novel coronavirus (also known as “2019-nCoV” and “SARS-CoV-2”) a Public Health Emergency of International Concern, and the United States Department of Health and Human Services (HHS) named it a public health emergency (PHE). In the United States, the declaration of a PHE empowers HHS to direct funding to: (1) allow the distribution of information about the virus; (2) encourage research and development of diagnostic and treatment techniques; (3) improve efforts on screening and detection; and (4) support local and state in efforts to restrain the spread of the virus. Working in tandem with HHS, the Centers for Disease Control and Prevention (CDC) continue to watch the outbreak closely, and a diagnostic test for the virus has already been fast-tracked by the U.S. Food and Drug Administration (FDA) through its emergency authorization power. The diagnostic test is only one example of the emergency activities we expect to see undertaken as federal and state agencies rush to respond to the 2019-nCoV outbreak.

In our full client alert, you will find an overview of information on the powers that enable state and federal governments to respond to a PHE, and the rules and regulations that are set forth by state and federal agencies concerning which health care providers, suppliers, and facilities may or must comply when a federal PHE has been declared or an infectious disease outbreak occurs under state law.

Photo of Scot Hasselman Scot Hasselman
Read more about Scot HasselmanEmailScot's Linkedin Profile
Photo of Celeste Letourneau Celeste Letourneau
Read more about Celeste LetourneauEmail
Photo of Joseph W. Metro Joseph W. Metro
Read more about Joseph W. MetroEmailJoseph's Linkedin Profile
Photo of Lesley Reynolds Lesley Reynolds
Read more about Lesley ReynoldsEmailLesley's Linkedin Profile
Photo of Nicole Aiken-Shaban Nicole Aiken-Shaban
Read more about Nicole Aiken-ShabanEmailNicole's Linkedin Profile
Photo of Jessica Christensen Jessica Christensen
Read more about Jessica ChristensenEmail
Photo of Arielle Lusardi Arielle Lusardi
Read more about Arielle LusardiEmail
Photo of Kristin Parker Kristin Parker
Read more about Kristin ParkerEmailKristin's Linkedin Profile
Photo of Janine Tougas Janine Tougas
Email
  • Posted in:
    Administrative and Regulatory
  • Blog:
    Life Sciences Legal Update
  • Organization:
    Reed Smith LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo